1.  Kotler L, Greenberg D, Givon-Lavi N, van der Beek BA, Dagan R, Ben-Shimol S. Decline in pneumococcal nasopharyngeal carriage in children 6-23 months with respiratory illnesses following pneumococcal conjugate vaccine implementation.  Vaccine 2021; 39:5757-5761

2. Danino D, van der Beek BA, Givon-Lavi N, Greenberg D, Ben-Shimol S, Dagan R. Unravelling the impact of pneumococcal conjugate vaccines on ambulatory antibiotic drug consumption in young children: an interrupted time series analysis. Clinical Infectious Diseases 2021:73:1268-1278

3. Song J-Y, Chang C-J, Andrews C, Diez-Domingo J, Oh M-D, Dagan R, Hartzel J, Pedley A, Li J, Sterling T, Tamms G, Chiarappa JA, Lutkiewicz J, Musey L, Tu Y, Buchwald UK on behalf of the V114-016 (PNEU-PATH) study group. Safety, tolerability, and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, followed by sequential PPSV23 vaccination in healthy adults aged ≥50 years: A randomized phase III trial (PNEU-PATH). Vaccine 2021;39:6422-6438.

4. Lewnard JA, Givon-Lavi N, Dagan R, Effectiveness of pneumococcal conjugate vaccines against community-acquired alveolar pneumonia attributable to vaccine-serotype Streptococcus pneumoniae among children. Clinical Infectious Diseases 2021:73:e1423- e1433